Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURE: Secukinumab in active non-infectious uveitis
NCT01095250Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of secukinumab in intermediate uveitis (IU), posterior uveitis, panuveitis, sponsored by Novartis. Started Apr 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
intermediate uveitis (IU)posterior uveitispanuveitis
Beyond the preview
Go deeper on NCT01095250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01095250.